3-(4-methoxyphenyl)-5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine | 1492680-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-(4-methoxyphenyl)-5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
• CAS: 1492680-76-8
• 化学式: C₂₀H₁₅BrN₂O₃S
• 分子量: 443.321
• InChiKey: UTUQYHHFAIZEQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  27.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  61.19
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  3-(4-methoxyphenyl)-5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 在 四(三苯基膦)钯 、 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 、 甲苯 为溶剂， 反应 3.5h， 生成 3-(4-methoxyphenyl)-5-(2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity

  摘要：

  A series of 3,5-diaryl-1H-pyrrolo[2,3-b]pyridines were synthesized and evaluated for inhibition of DYRKIA kinase in vitro. Derivatives having hydroxy groups on the aryl moieties (2c, 2j-l) demonstrated high inhibitory potencies with K(i)s in the low nanomolar range. Their methoxy analogues were up to 100 times less active. Docking studies at the ATP binding site suggested that these compounds bind tightly to this site via a network of multiple H-bonds with the peptide backbone. None of the active compounds were cytotoxic to KB cells at 10(-6) M. Kinase profiling revealed that compound 2j showed 2-fold selectivity for DYRK1A with respect to DYRK2 and DYRK3.

  DOI：

  10.1021/jm401049v
• 作为产物：
  描述：

  5-溴-3-碘-7-氮杂吲哚 在 四(三苯基膦)钯 、 苄基三乙基氯化铵 、 sodium hydride 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 水 、 甲苯 、 mineral oil 为溶剂， 反应 3.5h， 生成 3-(4-methoxyphenyl)-5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity

  摘要：

  A series of 3,5-diaryl-1H-pyrrolo[2,3-b]pyridines were synthesized and evaluated for inhibition of DYRKIA kinase in vitro. Derivatives having hydroxy groups on the aryl moieties (2c, 2j-l) demonstrated high inhibitory potencies with K(i)s in the low nanomolar range. Their methoxy analogues were up to 100 times less active. Docking studies at the ATP binding site suggested that these compounds bind tightly to this site via a network of multiple H-bonds with the peptide backbone. None of the active compounds were cytotoxic to KB cells at 10(-6) M. Kinase profiling revealed that compound 2j showed 2-fold selectivity for DYRK1A with respect to DYRK2 and DYRK3.

  DOI：

  10.1021/jm401049v

文献信息

• Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors
  作者：Hwangseo Park、Soyoung Lee、Suhyun Lee、Sungwoo Hong

  DOI：10.1039/c4ob00053f

  日期：——

  New 7-azaindole-based c-KIT inhibitors with nanomolar inhibitory activity and high selectivity for the gain-of-function D816V mutant were identified through the structure-based de novo design using the scoring function improved by implementing an accurate solvation free energy.

  通过使用改进的精确溶剂自由能的评分函数进行基于结构的全新设计，确定了具有纳摩尔抑制活性和对功能获得性D816V突变体高选择性的新型7-氮杂吲哚基c-KIT抑制剂。

• Application of Fragment-Based de Novo Design to the Discovery of Selective Picomolar Inhibitors of Glycogen Synthase Kinase-3 Beta
  作者：Hwangseo Park、Yongje Shin、Jinhee Kim、Sungwoo Hong

  DOI：10.1021/acs.jmedchem.6b00944

  日期：2016.10.13

  systematic fragment-based de novo design procedure was developed and applied to discover new potent and selective inhibitors of glycogen synthase kinase-3 beta (GSK3β). Candidate inhibitors were generated to simultaneously maximize the biochemical potency and the specificity for GSK3β through three design steps: identification of the optimal molecular fragments for the three sub-binding regions, design of

  开发了基于系统片段的从头设计程序，并将其应用于发现糖原合酶激酶-3β（GSK3β）的新的有效和选择性抑制剂。通过三个设计步骤生成候选抑制剂，以同时最大化GSK3β的生化效能和特异性：鉴定三个亚结合区的最佳分子片段，设计适当的连接部分以连接片段结构单元，以及对GSK3β的最终评分产生的分子。通过使用混合标度粒子理论和扩展的溶剂接触模型修改评分功能中的配体水合自由能术语，我们确定了几种GSK3β抑制剂，其生化潜能范围从低纳摩尔到皮摩尔水平。其中，两种最有效的抑制剂（12和27）预计将作为有希望的药物发现为因为高特异性GSK3β的抑制引起的GSK3β的各种疾病的起始点。
• Development and Biological Evaluation of Potent and Selective c-KIT^D816V Inhibitors
  作者：Soyoung Lee、Hyunseung Lee、Jinhee Kim、Suhyun Lee、Soo Jung Kim、Byong-Seok Choi、Soon-Sun Hong、Sungwoo Hong

  DOI：10.1021/jm500413g

  日期：2014.8.14

  The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT remains as a clinical challenge due to limited effective treatment options for therapies. For example, the acquired activating point mutation D816V significantly impairs the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular level will aid in designing and developing particular inhibitors with the potential to overcome these resistance mutations. We undertake a structure-based de novo design of 7-azaindole as the molecular core using the modified scoring function. This approach led to an identification of new c-KIT inhibitors over 100-fold specific for the D816V mutant relative to the wild-type c-KIT with nanomolar inhibitory activity. More importantly, these compounds potently inhibit clinically relevant D816V mutations of c-KIT in biochemical and cellular studies.